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Abstract
Background—Human papillomavirus (HPV) vaccine was recommended in 2006 for routine 
vaccination of US females aged 11–12 years. Most vaccine used through 2014 was quadrivalent 
vaccine (4vHPV), which prevents HPV-6, -11, -16, and -18 infection. To evaluate vaccine impact, 
we measured HPV prevalence in the National Health and Nutrition Examination Survey 
(NHANES).
Methods—We analyzed HPV DNA types detected in self-collected cervicovaginal specimens 
and demographic, sexual behavior, and self-reported vaccination data from females 14–34 years 
old. We estimated HPV prevalence in the prevaccine (2003–2006) and vaccine eras (2007–2010 
and 2011–2014).
Results—Among 14- to 19-year-olds, 4vHPV-type prevalence decreased from 11.5% (95% 
confidence interval [CI], 9.1%–14.4%) in 2003–2006 to 3.3% (95% CI, 1.9%–5.8%) in 2011–
2014, when ≥1-dose coverage was 55%. Among 20- to 24-year-olds, prevalence decreased from 
18.5% (95% CI, 14.9%–22.8%) in 2003–2006 to 7.2% (95% CI, 4.7%–11.1%) in 2011–2014, 
when ≥1-dose coverage was 43%. Compared to 2003–2006, 4vHPV prevalence in sexually active 
14- to 24-year-olds in 2011–2014 decreased 89% among those vaccinated and 34% among those 
unvaccinated. Vaccine effectiveness was 83%.
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Conclusions—Within 8 years of vaccine introduction, 4vHPV-type prevalence decreased 71% 
among 14- to 19-year-olds and 61% among 20- to 24-year-olds. Estimated vaccine effectiveness 
was high. The decrease in 4vHPV-type prevalence among unvaccinated females suggests herd 
protection.
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Persistent infection with human papillomavirus (HPV) can cause genital warts, cervical and 
other anogenital cancers, and head and neck cancers [1]. Three prophylactic vaccines are 
available that are highly effective against vaccine-type infections to prevent HPV-associated 
diseases [2, 3]. Routine vaccination has been recommended for females in the United States 
since mid-2006 and for males since 2011 [2, 4]. Vaccination is recommended for males and 
females at age 11 or 12 years, through age 26 years for females and through age 21 years for 
males who were not vaccinated previously. By 2014, almost all vaccine being used in the 
United States was quadrivalent (4vHPV) vaccine, which targets HPV types 6, 11, 16, and 
18; during this time, vaccination was recommended in a 3-dose schedule [5].
Since HPV vaccine introduction in 2006, coverage has increased but has remained lower 
than other immunizations recommended for adolescents. In 2008, coverage of ≥1 and 3 
doses of HPV vaccine among 13- to 17-year old girls was 37.2% and 17.9%, respectively; in 
2015, ≥1 and 3-dose coverage increased to 62.8% and 41.9% [6].
One of the early measures of vaccine impact is declines in vaccine-type infection. HPV 
testing in self-collected cervicovaginal swabs was incorporated into the National Health and 
Nutrition Examination Survey (NHANES) prior to vaccine introduction in 2003 and has 
been monitored in the vaccine era. Declines in vaccine-type prevalence have been 
documented, first among 14- to 19-year-olds within 4 years of vaccine introduction, and 
later among 20- to 24-year-olds within 6 years of vaccine introduction [7, 8].
In addition to declines in vaccine-type infection, further impacts of vaccination have been 
monitored. Prelicensure clinical trials suggested potential protective effects for some non-
vaccine types, specifically HPV-31, -33, and -45 [9, 10]. Some postlicensure monitoring 
studies have demonstrated decreases in nonvaccine types as well [11, 12], but previous 
NHANES analyses did not identify significant decreases among these specific HPV types 
[7, 8]. Additionally, assessing prevalence of specific nonvaccine types, to investigate 
potential type replacement, has been examined following vaccine introduction in different 
countries [13]. Finally, indirect protection for unvaccinated females, due to reduced 
prevalence of vaccine-preventable infections in the community, known as herd protection, 
has been evaluated and demonstrated in countries with high vaccine coverage [11, 14].
In the current analysis using NHANES data through 2014, we assessed type-specific HPV 
prevalence in the 8 years since vaccine introduction, compared to HPV prevalence prior to 
vaccine introduction. We also evaluated vaccine effectiveness, comparing HPV prevalence 
by self-reported vaccination status, as well as possible herd protection, type replacement, 
and cross-protection against related but non-4vHPV types.
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METHODS
Study Design
NHANES is an ongoing series of cross-sectional surveys conducted by the National Center 
for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC). The 
surveys are designed to be nationally representative of the civilian, noninstitutionalized US 
population. Surveys are conducted in approximately 15 counties, which vary each year. 
Consenting participants undergo a household interview followed by a physical examination 
in a mobile examination center (MEC). To increase the precision of estimates, NHANES 
oversampled various subpopulations in each cycle [15–17]. For example, from 1999 to 2006, 
adolescents aged 12–19 years were oversampled. Informed consent or assent was obtained 
from all participants and consent was obtained from guardians of minors. Data for girls aged 
14–17 years were obtained through the NCHS Research Data Center. This survey was 
approved by the NCHS/CDC Research Ethics Review Board.
Demographic, Behavioral, and HPV Vaccination History
Demographic information was ascertained during household interviews. Sexual history 
information was collected among participants aged 14–59 years by using audio computer-
assisted self-interviews in a MEC. Respondents who reported ever having sex (described as 
vaginal, oral, or anal sex) were asked additional questions about their sexual history. HPV 
vaccination history was collected beginning in 2007. Persons aged ≥16 years and 
emancipated minors were interviewed directly. Parents/guardians were interviewed 
regarding vaccination history for those aged <16 years.
Specimen Collection and Laboratory Methods
Females aged 14–59 years who were examined in a MEC were asked to self-collect a 
cervicovaginal sample. Extractions and testing were performed at the CDC as previously 
described [18, 19]. In brief, extracted DNA was tested by using the Research Use Only 
Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, Indianapolis, Indiana). 
The Linear Array assay uses L1 consensus polymerase chain reaction (PCR) followed by 
type-specific hybridization for qualitative detection of 37 HPV types (6, 11, 16, 18, 26, 31, 
33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 63, 66, 67, 68, 69, 70, 71, 72, 
73, 81, 82, 83, 84, 89, and IS39) and β-globin (control for sample amplification). Samples 
that tested negative for both HPV and β-globin were considered inadequate. A 
supplementary HPV-52 PCR assay was performed, as previously described [18].
Data Analysis
We analyzed NHANES data from 2003 to 2014. Analyses were limited to participants aged 
14–34 years with adequate self-collected cervicovaginal samples. From 2003 to 2014, a total 
of 8252 females aged 14–34 years were interviewed, and 6686 self-collected cervicovaginal 
swabs had adequate DNA for typing (Figure 1).
NHANES 2-year cycles were combined into 4-year eras to achieve stable estimates. For this 
analysis, cycles 2003–2004 and 2005–2006 were considered the prevaccine era because 
vaccination was first recommended in June 2006; 2007–2008 and 2009–2010 were 
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combined for the early vaccine era; and 2011–2012 and 2013–2014 were combined for the 
later vaccine era. Ages of participants were analyzed in 5- or 6-year age groups (14–19, 20–
24, 25–29, and 30–34). We analyzed self-reported receipt of ≥1 dose and 3 doses of HPV 
vaccine in 2007–2010 and 2011–2014; race/ethnicity, poverty index, and sexual behavior 
were compared across all 3 eras.
We defined sexually active females as females reporting any vaginal, oral, or anal sex, and 
defined vaccination as report of ≥1 HPV vaccine dose. Due to changes in race/ethnicity 
oversampling throughout the NHANES cycles, these categories were analyzed as non-
Hispanic white, non-Hispanic black, and other. We analyzed the number of lifetime sexual 
partners as a 3-level variable: none, 1–2, and ≥3; when limited to sexually active females, 
this was analyzed as 1–2 or ≥3.
HPV prevalence was determined in each era, by age group. HPV type categories evaluated 
include any of the 37 HPV types, any non-4vHPV types, non-4vHPV high-risk (HR) types 
(31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), 3 HR types with proposed cross-
protection (31, 33, 45), and 4vHPV types (6, 11, 16, 18). Prevalence of HPV was compared 
from the prevaccine era (2003–2006) to 2011–2014.
We limited analyses of vaccine effectiveness to sexually active females aged 14–24 years, to 
ensure all females included had a chance of exposure to HPV. To determine if the vaccinated 
and unvaccinated populations were comparable, we evaluated characteristics (race/ethnicity, 
poverty index, and sexual behavior) by era and by vaccination status. We assessed HPV 
prevalence among sexually active females aged 14–24 years and compared HPV prevalence 
by vaccination status in 2011–2014 to the prevaccine era, and within 2011–2014. We 
measured herd protection by comparing 4vHPV-type prevalence among unvaccinated 
females in the vaccine era years 2011–2014 to the prevaccine years 2003–2006. We 
estimated vaccine effectiveness by comparing 4vHPV-type prevalence among vaccinated and 
unvaccinated females within the vaccine era years 2011–2014. While females who did not 
recall vaccination status (n = 57) were included in the analysis of all females aged 14–34 
years, they were excluded from the analysis by vaccination history.
All estimates were generated by applying examination sample weights to account for 
unequal probabilities of selection and adjustment for nonresponse [20]. Variance estimates 
were calculated by using a Taylor series linearization to account for the complex survey 
design [21]. Logit confidence intervals (CIs) were calculated for prevalence estimates, with 
α = .05. Prevalence estimates with a relative standard error >30% are noted and are 
considered unstable. We calculated prevalence ratios (PRs) and adjusted prevalence ratios 
(aPRs) with 95% CIs, adjusting for race/ethnicity, poverty index, and number of lifetime 
sexual partners. The PR was the predicted probability calculated from the logistic regression 
model using the PREDMARG statement in SAS-callable SUDAAN [22]. Vaccine 
effectiveness was calculated as 100 × (1 − aPR). Statistical significance was defined as P < .
05 or, when prevalence ratios are presented, a 95% CI that does not include 1. Statistical 
analyses were conducted in SAS version 9.4 software (SAS Institute, Cary, North Carolina) 
and SUDAAN version 11.0 software (Research Triangle Institute, Research Triangle Park, 
North Carolina).
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RESULTS
Comparison of Prevaccine With Vaccine Eras by Age Group
Reported vaccination with ≥1 dose of HPV vaccine increased between 2007–2010 and 
2011–2014 in the age groups 14–19, 20–24, and 25–29 years (Table 1). In 2011–2014, 
54.7% of females aged 14–19 years, 43.0% aged 20–24 years, and 24.8% aged 25–29 years 
reported receipt of ≥1 dose. Compared with the prevaccine era, there was some variation in 
the distribution of race/ethnicity in the vaccine eras, but was only significant among the 14- 
to 19-year-old females. Additionally, there was a nonsignificant decrease in the percentage 
sexually active among 14- to 19-year-old females; however, the percentage with ≥3 lifetime 
partners remained stable. In females aged ≥20 years, >90% reported having had sex.
To assess the impact of vaccination on HPV prevalence, the prevalence of 4vHPV types was 
determined by age group. Among females aged 14–19 years, the prevalence of 4vHPV types 
decreased from 11.5% in 2003–2006, to 5.0% in 2007–2010, and 3.3% in 2011–2014 (aPR, 
0.29 [95% CI, .16–.53], comparing 2011–2014 to 2003–2006) (Table 2). There was also a 
decrease among females aged 20–24 years, from 18.5% in 2003–2006 to 7.2% in 2011–
2014 (aPR, 0.35 [95% CI, .21–.58]). No significant decreases were observed in 4vHPV 
types among older age groups. Some decreases were noted in any HPV, non-4vHPV, and 
non-4vHPV HR types among 14- to 19-year-olds in 2011–2014, compared with 2003–2006, 
but these were attenuated when adjusted for race/ethnicity, poverty index, and number of 
lifetime partners. No statistically significant decreases were found in any group for the 
combined measure of any HPV-31, -33, and -45 types, for which cross-protection has been 
suggested in other studies.
Prevalence of individual HPV types among females aged 14–19 and 20–24 years was 
assessed, comparing 2011–2014 to 2003–2006 (Figure 2; Supplementary Table 1). For 
individual 4vHPV types, the prevalence estimates were lower in 2011–2014, compared with 
2003–2006, among both age groups. No significant increases of non-4vHPV types were 
observed among those 14–19 years of age; the prevalence of 4 non-4vHPV types (HPV-33, 
-40, -56, -84) decreased in 2011–2014, compared with 2003–2006. Among 20- to 24-year-
old females, there were no significant increases or decreases in any non-4vHPV HR types; a 
significant increase was noted among 1 non-4vHPV type (HPV-73).
HPV Prevalence Among Sexually Active Females Aged 14–24 Years
Further analyses were limited to sexually active females aged 14–24 years, comparing 2011–
2014 to 2003–2006. Among this population, coverage of ≥1 HPV vaccine dose was 50.8% 
(95% CI, 40.1%–61.4%) in 2011–2014.
To assess potential population changes that could impact HPV prevalence, we evaluated age, 
race/ethnicity, poverty, and number of partners among sexually active females, comparing 
2011–2014 to 2003–2006 (Table 3). Overall, these characteristics did not differ significantly 
between the 2 time periods, except that sexually active females in 2011–2014 had a higher 
proportion with ≥3 sex partners. Vaccinated females in 2011–2014 did not differ 
significantly from females in the prevaccine era. However, compared to females in 2003–
2006, a higher proportion of unvaccinated females in 2011–2014 were nonwhite, older, and 
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reported ≥3 sex partners. To assess the potential contribution of these characteristics to 
estimates of vaccine effectiveness, vaccinated and unvaccinated females within 2011–2014 
were compared. Compared with unvaccinated females, a higher proportion of vaccinated 
females in 2011–2014 were non-Hispanic white, and a lower proportion were below the 
poverty index and aged 20–24 years; no differences in sexual behavior were noted.
Compared to 2003–2006, there was no significant increase or decrease in prevalence of any 
HPV, non-4vHPV types, non-4vHPV HR types, or proposed cross-protective types, overall 
or by vaccination status in 2011–2014 (Table 4). In the prevaccine era, 4vHPV-type 
prevalence was 18.5% among sexually active females aged 14–24 years. This was 
significantly lower among vaccinated females in 2011–2014, with a prevalence of 2.0% 
(aPR, 0.09 [95% CI, .04–.20]). Additionally, 4vHPV-type prevalence decreased to 12.2% 
among unvaccinated females in 2011–2014 (aPR, 0.60 [95% CI, .37–.98]).
Within the vaccine era years 2011–2014, no differences in prevalence were noted in 
vaccinated compared with unvaccinated females for any HPV, non-4vHPV, or non-4vHPV 
HR types. The 4vHPV-type prevalence was lower among vaccinated compared with 
unvaccinated females: 2.0% vs 12.2% (aPR, 0.17 [95% CI, .06–.50]). This corresponds to a 
vaccine effectiveness of 83%.
DISCUSSION
Within 8 years after HPV vaccine introduction in the United States, 4vHPV-type prevalence 
in cervicovaginal specimens decreased 71% among females aged 14–19 years and 61% 
among females aged 20–24 years, compared with the prevaccine era. There was no 
statistically significant decline in 4vHPV types among females aged 25–29 or 30–34 years. 
In an analysis of NHANES data within 4 years of HPV vaccine introduction, a 56% decline 
was observed among 14- to 19-year-olds [7]. In a subsequent analysis, within 6 years of 
vaccine introduction, in addition to a decline among 14- to 19-year-olds, a 34% decline was 
observed in 20- to 24-year-olds [8]. In the current analyses, larger decreases were observed 
in both 14- to 19-year-olds and 20- to 24-year-olds compared with past analyses, consistent 
with increasing vaccination coverage in these age groups.
We evaluated a variety of characteristics and behaviors of young women that, along with the 
HPV vaccination program, could have impacted trends in HPV prevalence. We noted some 
variation in race/ethnicity composition and poverty since 2003, similar to what has been 
observed in US census data [23, 24]. We also noted a slight decrease in the proportion of 
females aged 14–19 who report sexual activity; however, this was not statistically 
significant. Another study evaluating changes in adolescent sexual behavior found no 
decreases in adolescents reporting ever having sexual intercourse over the same time frame 
[25]. In our analysis, reductions in 4vHPV-type prevalence remained significant after 
multivariable adjustment for both demographics and sexual behaviors. Our findings of 
declining prevalence of 4vHPV types among females aged 14–19 years and 20–24 years are 
consistent with ecologic studies that have documented declines in genital warts and 
precancer lesions among women in their early 20s; however, these prior studies did not 
adjust for possible changes in sexual behavior [26, 27]. The specificity of declines to 4vHPV 
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types in our adjusted analyses further supports the conclusion that the vaccination program 
is primarily responsible for the observed declines in HPV prevalence.
We investigated herd effects of vaccination by evaluating prevalence among unvaccinated 
females aged 14–24 years in 2011–2014, compared with the prevaccine era. There was a 
34% decrease in 4vHPV-type prevalence among unvaccinated females. While herd 
protection from HPV vaccines has been demonstrated in other populations [11, 14, 28], this 
is the first NHANES analysis to show a statistically significant decline in 4vHPV-type 
prevalence among unvaccinated females. Herd protection can be affected by vaccine 
coverage; the population-level vaccine coverage required for herd protection varies by 
infectious agent [29, 30]. HPV prevalence studies reporting herd protection in other 
countries were conducted when vaccine coverage was >80% [11, 14], while studies in the 
United States reported herd protection with ≥1 dose HPV vaccine coverage of 60%–70% 
[28, 31]. In our analysis, herd protection is suggested with ≥1 dose coverage of 50%. Herd 
protection has also been suggested among males in a recent analysis of NHANES [32]. 
Vaccination of US males was not a routine recommendation until 2011, and ≥1 dose 
coverage among adolescent males was lower than for females during the study period. The 
herd effects suggested in the recent NHANES analysis among males are likely due, at least 
in part, to the female vaccination program.
Previous investigations of herd protection using NHANES data were impacted by 
differences in characteristics of women in the vaccine era by vaccination status compared 
with the pre-vaccine era, making it difficult to interpret changes in the prevalence among 
unvaccinated women [7]. In this analysis, we also found some differences, with a higher 
proportion of sexually active unvaccinated females in 2011–2014 having ≥3 sexual partners, 
compared to sexually active females in the prevaccine era. In spite of the greater number of 
partners in unvaccinated females, we observed a lower prevalence of 4vHPV types but not 
other HPV types in this group, which we interpret as evidence of herd protection in 2011–
2014.
This study estimated a vaccine effectiveness with ≥1 dose of HPV vaccine of 83%. This is 
lower than the >96% vaccine efficacy against vaccine-type precancer endpoints in the per 
protocol analyses reported in the clinical trials [33, 34]. However, our vaccine effectiveness 
estimate includes females who were likely infected prior to vaccination and some who did 
not receive the full vaccine series. As vaccine effectiveness compares infection or disease 
prevalence among vaccinated persons to unvaccinated persons, vaccine effectiveness could 
become difficult to accurately measure as herd effects decrease HPV prevalence in the 
unvaccinated population.
Clinical trials and some postlicensure monitoring studies demonstrated decreases in some 
non-4vHPV types, suggesting possible cross-protection [9–12]. However, significant 
decreases of non-4vHPV HR types have not been identified in previous NHANES analyses 
[7, 8]. In a meta-analysis by Drolet et al, data from 20 studies in 9 high-income countries 
were combined to evaluate effectiveness against vaccine types and potential cross-protection 
for HPV types 31, 33, or 45. They found evidence of reduced prevalence of the combined 
prevalence of HPV-31, -33, and -45 among females aged ≤19 years, but not among females 
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aged 20–24 years [35]. In this analysis, we did not find a statistically significant decline in 
the combined measure of HPV-31, -33, or -45 prevalence, but there was a significant 
decrease in HPV-33 among females 14–19 years of age. In studies to date, evidence of cross-
protection has varied by vaccine type, age group, and study population. In the future, it 
might be more difficult to assess cross-protection using future cycles of NHANES, as these 
3 types are targeted by the 9-valent HPV vaccine, introduced in the United States in 2015.
While type replacement is thought to be unlikely with HPV vaccination, studies in several 
countries have been monitoring type-specific HPV prevalence since vaccine introduction for 
increases in any non-4vHPV HR types. A meta-analysis of 9 studies of HPV prevalence 
reported increases in some non-4vHPV types, but these were inconsistent across studies for 
the 2 age groups examined [13]. No consistent increases in non-4vHPV types have been 
observed in prior NHANES analyses [7, 8]. In this analysis, at a period of higher vaccine 
coverage in the United States, there were no increases in non-4vHPV HR–type categories or 
individual non-4vHPV HR types. Overall, no increases were noted among any non-4vHPV 
types among females aged 14–19 years, and 1 non-high-risk non-4vHPV type increased 
among females aged 20–24 years; the clinical significance of this increase is unknown.
This analysis is subject to several limitations. First, vaccination history in NHANES is self-
reported; over or under-reporting could impact our vaccine effectiveness and herd protection 
estimates. Overall, however, HPV vaccine coverage estimates in our analysis are similar to 
nationwide estimates using vaccine provider–confirmed vaccination information [6]. 
Second, there were changes in the way some racial groups were sampled over time, and 
adolescents were not oversampled in all survey years. While this could impact precision, 
oversampling should not greatly impact our prevalence estimates over the survey years due 
to the weighted analysis. And finally, this study evaluated the prevalence of HPV from 
cervicovaginal infections at one time point, and therefore could not assess persistent 
infections or HPV-associated disease. The strengths of this study, including population-
based sampling, stable HPV testing methods used in all survey years, as well as 
demographic and behavioral data linked to laboratory data, allow for trends in HPV 
prevalence to be compared across multiple cycles, while controlling for population changes 
in sexual behaviors.
Since HPV vaccine was licensed and recommended, cervicovaginal 4vHPV-type prevalence 
has decreased in both 14- to 19-year-olds and 20- to 24-year-olds. High vaccine 
effectiveness was demonstrated in this analysis, and there was evidence of herd protection, 
with a decrease in HPV prevalence among unvaccinated females. Continued monitoring in 
NHANES will be important to evaluate the impact of a national vaccine program, including 
further herd protection and potential type replacement. Over time, we expect to observe 
decreases in prevalence among older age groups, as persons vaccinated at the recommended 
ages reach their late 20s and 30s. Monitoring will also allow evaluation of recent changes in 
recommendations. In 2015, a 9-valent HPV vaccine was introduced in the United States [3], 
and future analyses of NHANES will allow evaluation of changes in the 5 additional types 
targeted by that vaccine. In 2016, a 2-dose HPV vaccination schedule was recommended for 
persons initiating vaccination at ages 9–14 years [36]. Continued efforts are needed to 
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increase HPV vaccination coverage in the United States, and further impact can be 
anticipated with increased coverage among the targeted population.
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Figure 1. 
Participation and sample collection among females—National Health and Nutrition 
Examination Survey, 2003–2014. aThe response rate during 2003–2004 and 2005–2006 
among females was 79.7% and 80.9% for the interview portion and 76.0% and 77.8% for 
the examination portion, respectively. bThe response rate during 2007–2008 and 2009–2010 
among females was 78.6% and 79.7% for the interview portion and 75.5% and 77.4% for 
the examination portion, respectively. cThe response rate during 2011–2012 and 2013–2014 
among females was 72.6% and 71.4% for the interview portion and 69.4% and 68.8% for 
the examination portion, respectively.
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Figure 2. 
Prevalence of individual human papillomavirus (HPV) types among females aged 14–19 
years (A) and 20–24 years (B), National Health and Nutrition Examination Survey, 2003–
2006 and 2011–2014. *P < .05 based on Wald χ2 test, comparing 2011–2014 to 2003–2006. 
HPV types ordered from highest to lowest prevalence among 14- to 19-year-old females in 
2003–2006 within each HPV type category. Estimates with a relative standard error (RSE) 
of >30% to 50% are as follows: 14- to 19-year-old females: 2003–2006: HPV-11, -26, -33, 
-64, -71, -82; 2011–2014: HPV-6, -18, -31, -45, -53, -54, -55, -56, -61, -62, -68, -70, -73, 
-81, -82, -83. 20- to 24-year-old females: 2003–2006: HPV-31, -33, -35, -45, -55, -56, -67, 
-68, -73, -81, -82, -83; 2011–2014: HPV-18, -31, -40, -45, -58, -67, -70, -81, -82. Estimates 
with an RSE of >50% are as follows: 14- to 19-year-old females: 2003–2006: HPV-69, -72, -
IS39; 2011–2014: HPV-11, -16, -26, -33, -35, -40, -71, -72, -IS39. 20- to 24-year-old 
females: 2003–2006: HPV-11, -26, -40, -69, -71, -72, -IS39; 2011–2014: HPV-6, -11, -26, 
-33, -69, -71, -72, -IS39.
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Table 1
Reported Vaccination History, Demographic Characteristics, and Selected Sexual Behaviors in Females Aged 
14–34 Years, According to Age Group—National Health and Nutrition Examination Survey, 2003–2014
Age Group/Characteristic
Prevaccine Era (2003–2006)
% (95% CI)
Vaccine Era (2007–2010)
% (95% CI)
Vaccine Era (2011–2014)
% (95% CI)
14–19 y n = 1363 n = 740 n = 797
 HPV vaccination history
  ≥1 dose … 34.1 (28.4–40.3) 54.7 (49.6–59.7)a
  3 doses … 21.1 (15.8–27.6) 37.5 (32.7–42.6)a
 Race/ethnicity
  Non-Hispanic white 65.5 (58.9–71.6) 60.1 (54.4–65.6) 57.7 (50.2–64.9)a
  Non-Hispanic black 14.8 (11.0–19.7) 15.3 (12.1–19.0) 14.5 (10.2–20.3)
  Other 19.7 (15.6–24.4) 24.6 (20.1–29.8) 27.8 (23.2–32.8)
 Poverty index
  Below poverty 23.0 (18.7–27.9) 24.1 (19.6–29.3) 25.4 (20.0–31.6)
 Sexual behavior
  Ever had sex 54.0 (50.9–57.0) 50.3 (45.0–55.6) 48.2 (43.0–53.3)
  ≥3 lifetime sex partners 25.6 (22.5–29.0) 22.6 (19.9–25.5) 23.4 (19.4–27.9)
20–24 y n = 432 n = 445 n = 442
 HPV vaccination history
  ≥1 dose … 17.8 (12.4–24.9) 43.0 (36.0–50.4)a
  3 doses … 9.2 (5.4–15.2) 25.4 (19.5–32.3)a
 Race/ethnicity
  Non-Hispanic white 61.6 (54.6–68.2) 56.7 (49.0–64.2) 55.7 (46.9–64.1)
  Non-Hispanic black 15.7 (11.1–21.9) 15.9 (12.3–20.5) 16.6 (11.4–23.6)
  Other 22.6 (17.5–28.7) 27.3 (21.1–34.5) 27.7 (21.8–34.5)
 Poverty index
  Below poverty 25.7 (19.8–32.7) 31.8 (25.6–38.7) 35.7 (28.0–44.3)
 Sexual behavior
  Ever had sex 91.4 (86.1–94.8) 91.9 (88.3–94.5) 91.4 (86.9–94.5)
  ≥3 lifetime sex partners 60.7 (53.7–67.2) 71.8 (66.1–77.0) 68.4 (63.9–72.5)
25–29 y n = 403 n = 414 n = 395
 HPV vaccination history
  ≥1 dose … 7.8 (5.5–11.1) 24.8 (19.7–30.7)a
  3 doses … 3.8 (2.2–6.3) 17.1 (12.3–23.2)a
 Race/ethnicity
  Non-Hispanic white 65.0 (57.9–71.6) 63.6 (56.0–70.5) 56.4 (47.8–64.7)
  Non-Hispanic black 12.5 (8.9–17.4) 12.3 (8.7–17.2) 11.9 (8.6–16.2)
  Other 22.4 (17.3–28.6) 24.1 (19.6–29.3) 31.7 (25.4–38.8)
 Poverty index
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Age Group/Characteristic
Prevaccine Era (2003–2006)
% (95% CI)
Vaccine Era (2007–2010)
% (95% CI)
Vaccine Era (2011–2014)
% (95% CI)
  Below poverty 16.3 (12.5–21.0) 19.2 (16.3–22.5) 21.2 (16.9–26.1)
 Sexual behavior
  Ever had sex 95.0 (91.7–97.1) 95.6 (92.0–97.7) 95.4 (92.5–97.2)
  ≥3 lifetime sex partners 73.2 (66.4–79.0) 71.9 (66.7–76.6) 71.8 (64.9–77.8)
30–34 y n = 389 n = 433 n = 433
 HPV vaccination history
  ≥1 dose … 3.7 (2.0–6.7) 7.0 (4.6–10.4)
  3 doses … 1.3 (.6–3.0)b 4.2 (2.4–7.2)a
 Race/ethnicity
  Non-Hispanic white 61.8 (55.6–67.7) 58.1 (48.5–67.0) 59.7 (53.1–66.0)
  Non-Hispanic black 15.8 (11.6–21.2) 14.4 (9.9–20.5) 13.6 (10.2–18.0)
  Other 22.4 (17.7–27.8) 27.5 (20.9–35.4) 26.7 (21.1–33.1)
 Poverty index
  Below poverty 16.0 (12.7–20.1) 18.2 (13.9–23.4) 21.0 (16.6–26.2)
 Sexual behavior
  Ever had sex 98.4 (95.4–99.4) 97.4 (93.0–99.1) 99.1 (97.8–99.7)
  ≥3 lifetime sex partners 73.6 (68.2–78.4) 69.3 (63.5–74.6) 75.9 (70.0–81.0)
All prevalence estimates and 95% CIs are weighted.
Abbbreviations: CI, confidence interval; HPV, human papillomavirus.
aP < .05, comparing 2011–2014 to 2003–2006, except vaccination history compared 2011–2014 to 2007–2010; race/ethnicity compared as a 3-
level variable.
b
Relative standard error >30%.
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Table 3
Characteristics of Sexually Active Females Aged 14–24 Years, Overall and According to Vaccination History
—National Health and Nutrition Examination Survey, 2003–2006 and 2011–2014
Characteristics Prevaccine Era (2003–2006), % (95% CI)
Vaccine Era (2011–2014), % (95% CI)
Overall Vaccinated Unvaccinated
n = 1095 n = 707 n = 347 n = 360
Race/ethnicity
 Non-Hispanic white 64.0 (56.7–70.7) 56.6 (48.9–64.0) 63.2 (55.5–70.3)a 52.1 (42.3–61.8)b
 Non-Hispanic black 15.8 (11.4–21.4) 17.0 (11.7–24.1) 16.0 (11.0–22.7) 18.0 (11.8–26.4)
 Other 20.2 (15.9–25.4) 26.4 (21.8–31.7) 20.8 (15.8–26.9)a 29.9 (24.3–36.3)b
Poverty index
 Below poverty 27.5 (22.3–33.3) 33.0 (25.6–41.4) 27.4 (19.6–36.7)a 37.6 (28.9–47.1)
Sexual behavior
 ≥3 lifetime sex partners 58.4 (54.9–61.7) 65.3 (60.9–69.5)b 63.9 (56.8–70.4) 67.0 (59.3–73.9)b
Age, y
 20–24 57.1 (53.7–60.6) 63.7 (57.5–69.5) 58.1 (50.5–65.2)a 69.3 (61.8–75.9)b
All prevalence estimates and 95% CIs are weighted.
Abbreviation: CI, confidence interval.
aComparison of vaccinated with unvaccinated, within 2011–2014, P < .05.
bComparison of 2011–2014 to 2003–2006, P < .05.
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Table 4
Human Papillomavirus Prevalence Among Sexually Active Females Aged 14–24 Years, Overall and 
According to Vaccination History—National Health and Nutrition Examination Survey, 2003–2006 and 2011–
2014
Prevaccine Era (2003–2006) Vaccine Era (2011–2014)
Comparison of 
2011–2014 to 
2003–2006 Comparison Within 2011–2014
HPV Typesa/Vaccination Status % (95% CI) % (95% CI) aPR (95% CI)b aPR (95% CI)b
Any HPV
 Overall 54.3 (49.4–59.1) 57.0 (52.1–61.8) 0.99 (.89–1.11) …
 Vaccinated … 58.4 (51.6–64.9) 1.04 (.92–1.19) 1.07 (.90–1.28)
 Unvaccinated … 57.1 (49.9–64.0) 0.97 (.83–1.13) Ref
Non-4vHPV
 Overall 51.1 (46.4–55.8) 56.4 (51.5–61.2) 1.04 (.93–1.17) …
 Vaccinated … 58.2 (51.3–64.8) 1.11 (.97–1.27) 1.09 (.91–1.30)
 Unvaccinated … 56.1 (48.9–63.0) 1.01 (.85–1.19) Ref
Non-4vHPV HR
 Overall 32.7 (28.9–36.9) 35.1 (29.3–41.4) 1.02 (.84–1.24) …
 Vaccinated … 34.2 (26.9–42.4) 1.01 (.79–1.30) 0.95 (.68–1.33)
 Unvaccinated … 36.7 (28.5–45.8) 1.05 (.80–1.39) Ref
HPV types 31, 33, 45
 Overall 6.6 (4.7–9.2) 4.9 (3.1–7.6) 0.75 (.42–1.32) …
 Vaccinated … 4.9 (2.9–8.2) 0.70 (.36–1.37) 0.86 (.43–1.74)
 Unvaccinated … 5.0 (2.7–9.1) 0.82 (.41–1.64) Ref
4vHPV
 Overall 18.5 (16.1–21.2) 7.1 (4.7–10.5) 0.33 (.23–.49) …
 Vaccinated … 2.0 (1.0–3.9)c 0.09 (.04–.20) 0.17 (.06–.50)
 Unvaccinated … 12.2 (7.6–19.2) 0.60 (.37–.98) Ref
All prevalence estimates and 95% CIs are weighted.
Abbreviations: 4vHPV, quadrivalent human papillomavirus; aPR, adjusted prevalence ratio; CI, confidence interval; HPV, human papillomavirus; 
PR, prevalence ratio.
aAny HPV: HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 63, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 
83, 84, 89, IS39. Non-4vHPV: HPV types 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 63, 66, 67, 68, 69, 70, 71, 72, 73, 81, 
82, 83, 84, 89, IS39. Non-4vHPV HR: HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. 4vHPV: HPV types 6, 11, 16, 18.
bAdjusted for race/ethnicity, poverty index, and number of lifetime partners.
c
Relative standard error >30%.
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